Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up
-
Published:2024-06
Issue:
Volume:134
Page:112192
-
ISSN:1567-5769
-
Container-title:International Immunopharmacology
-
language:en
-
Short-container-title:International Immunopharmacology
Author:
Salehi Mohammadreza,
Alavi Darazam Ilad,
Nematollahi Alireza,
Alimohammadi Masoumeh,
Pouya Sedigheh,
Alimohammadi Reza,
Khajavirad Nasim,
Porgoo MeysamORCID,
Sedghi Mosslim,
Mahdi Sepahi Mohammad,
Azimi Maryam,
Hosseini HamedORCID,
Mahmoud Hashemi Seyed,
Dehghanizadeh Somaye,
Khoddami VahidORCID